ClinicalTrials.gg
RecruitingNCT06624709BienFERUpdated May 25, 2025

The Benefit in Terms of Improvement in Haemoglobin Level at 6 Months in Premature Babies Receiving Alternate Iron Substitution 4 Times a Week Compared to a Daily Substitution

An interventional study of Iron Supplement in Premature Birth, sponsored by Riccardo Pfister. Recruiting at 2 sites in Switzerland. Open to participants aged 14 Days to 14 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-25.

Sponsored by Riccardo Pfister · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
14 Days to 14 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Premature Birth with a site in Switzerland — 12 open to participants now, 14 under way, none of them phase 3. Premature Birth · Switzerland.

Planned enrollment
6th of 20
160 · median 57
Started
2024
with 2 others
No phase
15 of 34
6 open now
Primary completion
2026-09
later than 9 of 13 live
Registered
28th of 34
by date

Among the 34 studies in Premature Birth with a site in Switzerland, this one is the 6th largest by planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2024, is one of 15 with no phase, reaches primary completion later than 9 of the 13 other live ones, and was the 28th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

12 of the 34 studies in Premature Birth with a site in Switzerland are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 14 Days to 14 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Premature Birth with a site in Switzerland, or all of them as a file.
02

Study summary

BienFer is a double-blinded randomized controlled trial about iron substitution and abdominal pain. Premature babies and low birth weight babies have lower iron stores than term newborns and are therefore at greater risk of iron deficiency and anemia. Iron deficiency could have consequences for cerebral development. Ferric substitution reduces the risk of iron deficiency and anemia. It is common to replace premature babies with iron substitution between 2 weeks and 6 months of life. In practice, the medical staff notice that newborn with iron substitution have abdominal pain and constipation. A study in the adult population shows that alternate iron supplementation versus daily supplementation improved iron absorption, with no difference in hemoglobin level and decrease abdominal pain. Studies in children shows that intermittent iron supplementation do not change hemoglobin and ferritin level and improve adherence. There is no data comparing daily versus alternate supplementation in premature babies.

The aim of the study is to evaluate if alternate (4 times/week) iron supplementation is equivalent to daily iron substitution for hemoglobin values in premature babies between 28 0/7 weeks amenorrhea (WA) and 34 6/7 WA, and if it reduces abdominal discomfort and inflammation, and if it improves compliance.

03

Conditions studied

  • Premature Birth

Browse trials for

04

Who can participate

Ages eligible
14 Days to 14 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Premature babies between 28 0/7WA and 34 6/7 WA
  • Parental consent, postnatal
  • Age of 2 weeks

Exclusion criteria

Exclusion Criteria:

  • anemia \< 80g/l at 2 weeks of age
  • Intraventricular Hemorrhage stage III and IV
  • Necrotizing Enterocolitis
  • Enteral feeding less than 100ml/kg/j after 2 weeks of life
  • Congenital disorder
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Investigator)
Enrollment
160 participants (estimated)

Study arms

  • Active comparator
    Alternate (4 times/week) iron supplementation

    This arm will receive 2-3mg/kg/d of maltofer 4 times a day

    Drug: Iron Supplement

  • Sham comparator
    Daily iron substitution

    This arm will receive 2-3mg/kg/d of maltofer 7 times per week.

    Drug: Iron Supplement

Interventions

  • The interventional group will receive 2-3mg/kg/day of iron supplementation 4 times per week and the sham comparator will receive 2-3mg/kg/day of iron supplementation 7 times per week

06

What researchers measure

Primary outcomes

  1. Anemia at 6 months

    Hemoglobin level

    Time frame: 6 months

Secondary outcomes

  1. Anemia

    Hemoglobin

    Time frame: at 2weeks, 1 month, 2-3 months

  2. Anemia

    Hematocrit level

    Time frame: at 2weeks, 1 month, 2-3 months

  3. Ferritin

    Ferritin

    Time frame: at 2 weeks, 1 month, 2-3 months and 6 months

  4. Ret-Hb level

    Ret-Hb level

    Time frame: at 2 weeks, 1 month, 2-3 months and 6 months

  5. Transfusion

    Number of patients needed a transfusion

    Time frame: at 1 month, 2-3 months and 6 months

  6. Therapeutic level

    Number of patients needed to increase the iron substitution to a therapeutic level

    Time frame: at 1 month, 2-3 months and 6 months

  7. Evaluation of abdominal inflammation

    Calprotectin level

    Time frame: at 2 weeks and 2-3 months

  8. Evaluation of abdominal inflammation

    Hepcidin level

    Time frame: at 2 weeks and 2-3 months

  9. Evaluation of intestinal microbiota

    Fecal sequencing

    Time frame: at 2-3 months

  10. Comorbidities

    Number of retinopathy of prematurity (ROP)

    Time frame: at 6 months

  11. Comorbidities

    Number of periventricular leukomalacia (PVL)

    Time frame: at 6 months

  12. Comorbidities

    Number of sepsis

    Time frame: at 6 months

  13. Comorbidities

    Number of intraventricular hemorrhage (IVH)

    Time frame: at 6 months

  14. Comorbidities

    Number of bronchopulmonary dysplasia (BPD)

    Time frame: at 6 months

  15. Comorbidities

    Number of necrotizing enterocolitis (NEC)

    Time frame: at 6 months

  16. Evaluation of weight gain

    Tracking weight in Kilograms

    Time frame: at 2 weeks, 1 month, 2-3 months and 6 months

  17. Evaluation of height gain

    Tracking height in Centimeters

    Time frame: at 2 weeks, 1 month, 2-3 months and 6 months

  18. Evaluation of the growth's parameter

    Tracking head circumference in Centimeters

    Time frame: at 2 weeks, 1 month, 2-3 months and 6 months

  19. Evaluation of abdominal discomfort

    Edin scale (0 (better outcome, no pain)-15 (worse outcome, pain))

    Time frame: 3 times per week during hospitalization then 1 time per 2 weeks until 6 months

  20. Evaluation of abdominal discomfort

    Classify stools with Bristol scale (1 (severe constipation) -7 (severe diarrhea))

    Time frame: 3 times per day during hospitalization then 1 time per 2 weeks until 6 months

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Sep 2026, 22 months after the start.

Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 22 months is close to that.

Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2024
First posted
Oct 3, 2024
StartActual
Nov 2, 2024
Primary completionEst.
Sep 16, 2026
CompletionEst.
May 2027
Last update
May 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06624709
Lead sponsor
Riccardo Pfister
Responsible party
Riccardo Pfister (Head of neonatology department, Principal Investigator, Clinical Professor, University Hospital, Geneva) — Sponsor-investigator
First posted
Oct 3, 2024
Start date
Nov 2, 2024
Primary completion
Sep 16, 2026 (estimated)
Completion
May 2027 (estimated)
Last update
May 25, 2025

Study contacts

Céline Ferraz
Contact
celine.ferraz@hcuge.ch
+41 79 553 84 54
Riccardo E Pfister, MD, PHD
Contact
riccardo.pfister@hug.ch
+41 79 553 44 38

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron Supplement

Start the discussion